阿斯利康AstraZeneca plc (AZN) 2018年年度报告「LSE」.pdf

1、What science can doAstraZeneca Annual Report and Form 20-F Information 2018Front cover image:Circulating tumour DNAAstraZeneca has pioneered theuse of circulating tumour DNA(ctDNA)in the diagnosis ofcancer.Pieces of DNA break offfrom a tumour and circulate in the bloodstream where they can be analys

2、ed to give genetic information about a patients tumour.This allows healthcare professionals to determine the right treatment for the patient using a minimally invasive blood test.canScienceWelcomeInnovative Value Strategies and indication-based pricing See page 17Innovative ideas in healthcare See p

3、age 37Searching for new treatment options See page 49Pioneering the use of circulating tumour DNA See page 28New ways of treating heartdisease See page 61Use of termsIn this Annual Report,unless thecontext otherwise requires,AstraZeneca,the Group,we,us and our refer to AstraZeneca PLC and its consol

4、idated entities.We are a global,science-led pharmaceutical business,and in this Annual Report we report onthe progress we made in 2018 in pushing theboundaries of science to deliver life-changing medicines and demonstrating what science can do.deliver complete disease management in Chinadeliver valu

5、e to patients,payers andsocietyhelp find a cure for ovarian cancerimprove the diagnosis andtreatment of cancerhelp people undergoing heartbypass surgeryContents201820172016$22,465m$23,002m201820172016$2,618m$3,578m$4,145m$3,387m$3,677m$4,902m$5,672m$6,855m$6,721m$1.70$2.37$2.77$3.46$4.28$4.31$22,090

6、m$22.1bn$2.6bn201820172016201820172016$3.4bn$5.7bn201820172016201820172016$1.70$3.46Corporate GovernanceChairmans Introduction 92Corporate Governance Overview 93Board of Directors 94Senior Executive Team 96Corporate Governance Report 98Science Committee Report 107Nomination and Governance Committee